Cervical Cancer Vaccine Market

The cervical cancer vaccine, also known as the HPV vaccine, is a type of vaccine that protects against human papillomavirus (HPV) infection.Medical research shows that 99.7 percent of cervical cancers are caused by HPV.A fair number of the 160 countries around the world that use the vaccine call it the "cervical cancer vaccine", though this is not strictly enough.Internationally, the HPV vaccine is believed to be effective in preventing all women between the ages of 9 and 45, and can reduce the incidence of cervical cancer and precancerous lesions by up to 90 percent if women are given the HPV vaccine before their first sexual encounter.On April 22, xiamen wantai canghai biotechnology co., ltd. produced the first batch of 93,643 domestic bivalent human papillomavirus vaccines, which were approved by the national medical products administration.

Cervical Cancer Vaccine Market contains market size and forecasts of Cervical Cancer Vaccine in global, including the following market information:

• Global Cervical Cancer Vaccine Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global Cervical Cancer Vaccine Market Sales, 2017-2022, 2023-2028, (K Units)
• Global top five Cervical Cancer Vaccine companies in 2021 (%)

The global Cervical Cancer Vaccine market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

2 Valent Vaccine Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Cervical Cancer Vaccine include GSK, MSD, Walvax Biotechnology and Wantai Biological Pharmacy, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Cervical Cancer Vaccine manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Cervical Cancer Vaccine Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Cervical Cancer Vaccine Market Segment Percentages, by Type, 2021 (%)

• 2 Valent Vaccine
• 4 Valent Vaccine
• 9 Valent Vaccine

Global Cervical Cancer Vaccine Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Cervical Cancer Vaccine Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Biotechnology Company
• Academic And Research Organizations
• Other

Global Cervical Cancer Vaccine Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Cervical Cancer Vaccine Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Cervical Cancer Vaccine revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Cervical Cancer Vaccine revenues share in global market, 2021 (%)
• Key companies Cervical Cancer Vaccine sales in global market, 2017-2022 (Estimated), (K Units)
• Key companies Cervical Cancer Vaccine sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• GSK
• MSD
• Walvax Biotechnology
• Wantai Biological Pharmacy